
Seafarers Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2021
made under paragraph 10(1)(b) of the Seafarers Rehabilitation and Compensation Act 1992
Compilation No. 1
Compilation date: 21 March 2026
Includes amendments: F2026L00289
About this compilation
This compilation
This is a compilation of the Seafarers Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2021 that shows the text of the law as amended and in force on 21 March 2026 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au).
Application, saving and transitional provisions
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. Any modifications affecting the law are accessible on the Register.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
This instrument is the Seafarers Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2021.
This instrument is made under paragraph 10(1)(b) of the Seafarers Rehabilitation and Compensation Act 1992.
In this instrument:
Act means the Seafarers Rehabilitation and Compensation Act 1992.
disease has its ordinary meaning.
substance means any natural or artificial substance, whether in the form of a solid, liquid, gas or vapour.
This instrument applies in relation to a disease that an employee suffers on or after the day this instrument commences.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
For the purposes of paragraph 10(1)(b) of the Act, a disease of a kind specified in column 1 of an item of the table in Schedule 1 is a disease related to employment of a kind specified in column 2 of that item.
This instrument is repealed on 1 April 2028.
| Column 1 | Column 2 |
Item | Disease | Employment |
Infectious diseases | ||
1 | Anthrax | Employment involving work with:
|
2 | Brucellosis | Employment involving work with:
|
3 | Hepatitis A | Employment involving work with human waste. |
4 | Hepatitis B or Hepatitis C | Employment involving work with human body fluids. |
5 | Human Immunodeficiency Virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) | Employment involving work with:
|
6 | Leptospirosis | Employment involving work with:
|
7 | Orf | Employment involving work with:
|
8 | Q-fever | Employment involving work with:
|
9 | Tuberculosis | Employment involving work with:
(i) in a farming setting; or (ii) in a veterinarian setting; or
(i) in a farming setting; or (ii) in a veterinarian setting; or
(i) in a healthcare services setting; or (ii) in a mortuary setting; or
|
10 | Malaria | Employment involving work in a region where malaria is endemic. |
Malignant diseases | ||
11 | Primary malignant disease of the salivary gland | Employment for at least 5 years (whether consecutive or not) involving work with:
|
12 | Primary malignant disease of the nasopharynx | Employment for at least 5 years (whether consecutive or not) involving work with:
|
13 | Primary malignant disease of the oesophagus | Employment for at least 5 years (whether consecutive or not) involving work with:
|
14 | Primary malignant disease of the stomach | Employment for at least 5 years (whether consecutive or not) involving work with:
|
15 | Primary malignant disease of the colon or rectum | Employment for at least 5 years (whether consecutive or not) involving work with:
|
16 | Primary malignant disease of the liver | Employment for at least 5 years (whether consecutive or not) involving work with vinyl chloride monomer. |
17 | Primary malignant disease of the nasal cavity or para-nasal sinuses | Employment for at least 5 years (whether consecutive or not) involving work with:
|
18 | Primary malignant disease of the larynx | Employment for at least 5 years (whether consecutive or not) involving work with:
|
19 | Primary malignant disease of the lung caused by asbestos | Employment for at least 5 years (whether consecutive or not) involving work with:
|
20 | Primary malignant disease of the bone | Employment for at least 5 years (whether consecutive or not) involving work with:
|
21 | Primary malignant disease of the mesothelium | Employment for at least three months (whether consecutive or not) involving work with:
|
22 | Primary malignant disease of the breast | Employment for at least 5 years (whether consecutive or not) involving work with:
|
23 | Primary malignant disease of the ovary | Employment for at least 5 years (whether consecutive or not) involving work with:
|
24 | Primary malignant disease of the kidney | Employment for at least 5 years (whether consecutive or not) involving work with:
|
25 | Primary malignant disease of urothelial tissue lining the urinary tract | Employment for at least 5 years (whether consecutive or not) involving work with:
|
26 | Primary malignant disease of the brain | Employment for at least 5 years (whether consecutive or not) involving work with:
|
27 | Primary malignant disease of the thyroid | Employment for at least 5 years (whether consecutive or not) involving work with:
|
28 | Primary leukaemia (excluding chronic lymphatic leukaemia) | Employment for at least 2 years (whether consecutive or not) involving work with:
|
29 | Primary non-Hodgkins lymphoma | Employment for at least 2 years (whether consecutive or not) involving work with:
|
30 | Cholangiocarcinoma | Employment for at least 5 years (whether consecutive or not) involving work with 1,2 Dichloropropane. |
31 | Ocular melanoma | Employment for at least 5 years (whether consecutive or not) involving work with welding (producing ultraviolet light). |
Diseases of the nervous system | ||
32 | Parkinson’s disease | Employment for at least one year (whether consecutive or not) involving work with manganese. |
33 | Peripheral neuropathy | Employment for at least one year (whether consecutive or not) involving work with:
|
Respiratory diseases | ||
34 | Occupational asthma | Employment for at least 4 weeks (whether consecutive or not) involving work with an agent or thing specified in column 2 of an item of the table in Schedule 2. |
35 | Coal workers’ pneumoconiosis | Employment for at least 5 years (whether consecutive or not) involving work with coal. |
36 | Asbestosis | Employment for at least 5 years (whether consecutive or not) involving work with:
|
37 | Silicosis | Employment for at least 5 years (whether consecutive or not) involving work with:
|
38 | Other pneumoconiosis | Employment for at least 5 years (whether consecutive or not) involving work with:
|
39 | Byssinosis | Employment for at least 4 weeks (whether consecutive or not) involving work with:
|
40 | Extrinsic allergic alveolitis | Employment for at least 4 weeks (whether consecutive or not) involving work with:
|
Hepatic disease | ||
41 | Non-infectious hepatitis | Employment involving work with:
(za) organochlorine compounds; or (zb) organophosphate; or (zc) osmium; or (zd) oxides of nitrogen; or (ze) ozone; or (zf) phosgene; or (zg) phosphorus; or (zh) selenium; or (zi) styrene; or (zj) thallium; or (zk) tin; or (zl) toluene; or (zm) toxic halogen derivatives of aliphatic; or (zn) toxic nitro-derivatives of benzene; or (zo) vanadium; or (zp) zinc. |
Skin diseases | ||
42 | Irritant contact dermatitis | Employment for at least 4 weeks (whether consecutive or not) involving work and contact with:
|
43 | Allergic contact dermatitis | Employment for at least 4 weeks (whether consecutive or not) involving work and contact with:
(i) amylcinnamaldehyde; or (ii) cinnamic alcohol; or (iii) cinnamic aldehyde; (iv) eugenol; or (v) geraniol; or (vi) hydroxycitronellal; or (vii) isoeugenol; or (viii) oakmoss absolute; or
(i) citral; or (ii) citronellol; or (iii) coumarin; or (iv) farnesol; or (v) hexyl cinnamic aldehyde; or (vi) hydroxyisohexyl 3-cyclohexene carboxaldehyde; or
(i) tetramethylthiuramdisulfide; or (ii) tetramethylthiuram monosulfide; or (iii) tetraethylthiuram disulfide. |
44 | Occupational vitiligo | Employment for at least 4 weeks (whether consecutive or not) involving work with:
|
Musculoskeletal diseases | ||
45 | Raynaud’s disease | Employment for at least 12 weeks (whether consecutive or not) involving work with:
|
46 | Bursitis at the elbow or knee | Employment for at least 6 months (whether consecutive or not) involving a work activity that:
(i) involves prolonged external friction at or about the elbow; or (ii) involves prolonged external pressure at or about the elbow; or (iii) involves recurrent external friction at or about the elbow; or (iv) involves recurrent external pressure at or about the elbow; or
(i) involves prolonged external friction at or about the knee; or (ii) involves prolonged external pressure at or about the knee; or (iii) involves recurrent external friction at or about the knee; or (iv) involves recurrent external pressure at or about the knee. |
Acute diseases | ||
47 | Acute poisoning or toxicity affecting the heart, lungs, liver, kidney, nervous system or blood | The same as for item 38. |
| Column 1 | Column 2 |
Item | Class of agent or thing | Specified agent or thing |
1 | Arthropods |
|
2 | Acids |
|
3 | Acrylates |
|
4 | Aldehydes |
|
5 | Amines |
|
6 | Ammonias |
|
7 | Anhydrides |
|
8 | Bio-aerosols |
|
9 | Biological enzymes |
|
10 | Epoxy |
|
11 | Ethylene oxide | ethylene oxide. |
12 | Flours |
|
13 | Flowers |
|
14 | Foods |
|
15 | Industrial cleaning and sterilising agents |
|
16 | Isocyanates |
|
17 | Latex |
|
18 | Medications |
|
19 | Metals |
|
20 | Other reactive chemicals |
|
21 | Pesticides |
|
22 | Plants and sensitising agents or irritants derived from plants |
|
23 | Reactive dyes |
|
24 | Sensitising agents or irritants derived from animals |
|
25 | Sensitising agents or irritants derived from fish or shellfish |
|
26 | Soldering fluxes |
|
27 | Wood |
|
|
|
|
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.
If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.
ad = added or inserted | orig = original |
am = amended | p = page(s) |
amdt = amendment | para = paragraph(s)/subparagraph(s) |
C[x] = Compilation No. x | /sub‑subparagraph(s) |
ch = Chapter(s) | pres = present |
cl = clause(s) | prev = previous |
cont. = continued | (prev…) = previously |
def = definition(s) | pt = Part(s) |
Dict = Dictionary | r = regulation(s)/Court rule(s) |
disallowed = disallowed by Parliament | reloc = relocated |
div = Division(s) | renum = renumbered |
exp = expires/expired or ceases/ceased to have | rep = repealed |
effect | rs = repealed and substituted |
gaz = gazette | s = section(s)/subsection(s) |
LA = Legislation Act 2003 | /rule(s)/subrule(s)/order(s)/suborder(s) |
LIA = Legislative Instruments Act 2003 | sch = Schedule(s) |
(md not incorp) = misdescribed amendment | SLI = Select Legislative Instrument |
cannot be given effect | SR = Statutory Rules |
mod = modified/modification | sub ch = Sub‑Chapter(s) |
No. = Number(s) | sub div = Subdivision(s) |
Ord = Ordinance | sub pt = Subpart(s) |
| underlining = whole or part not |
| commenced or to be commenced |
Name | Registration | Commencement | Application, saving and transitional provisions |
Seafarers Rehabilitation and Compensation (Specified Diseases and Employment) Instrument 2021 | 29 March 2021 (F2021L00360) | 30 March 2021 |
|
Seafarers Rehabilitation and Compensation Amendment (Specified Diseases and Employment) Amendment Instrument 2026 | 20 March 2026 (F2026L00289) | 21 March 2026 (s2)) |
|
Provision affected | How affected |
s2 s8 | rep LA s 48D am F2026L00289 |
Schedule 3 | rep LA s48C |